BIRC5 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, survivin reduces the effectiveness of targeted therapies, such as Imatinib in chronic myeloid leukemia (CML) (Speletas et al., 2011; Carter et al., 2006) and Gefitinib in lung cancer (Zhou et al., 2018).